Comparing the Costs and Diagnostic Outcomes of Replacing Cytology with the QIAsure DNA Methylation Test as a Triage within HPV Primary Cervical Cancer Screening in The Netherlands

Detecting hypermethylation of tumour suppressor genes could provide an alternative to liquid-based cytology (LBC) triage within HPV primary cervical screening. The impact of using the QIAsure ® FAM19A4/mir124-2 DNA Methylation Test (QIAGEN, N.V, Hilden, Germany) on CIN3+ diagnoses, retention, unnecessary colposcopies, and programme costs is unknown. A decision-tree model was developed to compare LBC with the QIAsure Methylation testing to guide colposcopy referral. Incorporating clinician- and self-sampling pathways the model was informed by the Dutch cervical cancer screening programme, publi... Mehr ...

Verfasser: Krishnan Puri Sudhir
Eva Kagenaar
Michelle Meijer
Albertus T. Hesselink
Elisabeth Adams
Katy M. E. Turner
Susie Huntington
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: Diagnostics, Vol 13, Iss 24, p 3612 (2023)
Verlag/Hrsg.: MDPI AG
Schlagwörter: human papillomavirus infections / early detection of cancer / cost–benefit analysis / uterine cervical neoplasms / DNA methylation / The Netherlands / Medicine (General) / R5-920
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29171928
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3390/diagnostics13243612